Growth Opportunities F. Forbion Buys 341,332 Shares of enGene Holdings Inc. (NASDAQ:ENGN) Stock

enGene Holdings Inc. (NASDAQ:ENGN) major shareholder Growth Opportunities F. Forbion bought 341,332 shares of the company’s stock in a transaction dated Monday, September 30th. The shares were purchased at an average price of $6.34 per share, with a total value of $2,164,044.88. Following the transaction, the insider now owns 2,400,791 shares of the company’s stock, valued at $15,221,014.94. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Large shareholders that own at least 10% of a company’s stock are required to disclose their sales and purchases with the SEC.

enGene Trading Down 3.0 %

ENGN traded down $0.28 during midday trading on Friday, reaching $9.02. 110,205 shares of the company were exchanged, compared to its average volume of 113,105. The company has a debt-to-equity ratio of 0.09, a quick ratio of 19.52 and a current ratio of 19.52. enGene Holdings Inc. has a one year low of $4.42 and a one year high of $43.00. The stock has a market capitalization of $398.38 million, a P/E ratio of -5.41 and a beta of -0.69. The stock’s 50-day simple moving average is $6.66 and its 200 day simple moving average is $9.83.

enGene (NASDAQ:ENGN) last issued its earnings results on Tuesday, September 10th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.05. As a group, analysts forecast that enGene Holdings Inc. will post -1.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on ENGN. Oppenheimer reiterated an “outperform” rating and set a $30.00 price target on shares of enGene in a research report on Tuesday, September 24th. Morgan Stanley reissued an “overweight” rating and issued a $40.00 price target on shares of enGene in a research note on Wednesday, September 11th. Seven equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of “Buy” and a consensus target price of $33.67.

Hedge Funds Weigh In On enGene

Several institutional investors and hedge funds have recently modified their holdings of ENGN. Altitude Crest Partners Inc. acquired a new stake in enGene during the 1st quarter worth approximately $2,039,000. SR One Capital Management LP bought a new stake in shares of enGene during the second quarter worth $4,715,000. Janus Henderson Group PLC acquired a new stake in shares of enGene during the first quarter worth $17,095,000. Finally, Logos Global Management LP lifted its position in enGene by 50.0% in the 2nd quarter. Logos Global Management LP now owns 1,200,000 shares of the company’s stock valued at $11,316,000 after acquiring an additional 400,000 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors and hedge funds.

enGene Company Profile

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.